Showing 36,902 results

Filters
Cardiovascular disease

Why a major finding on HIV and statins may not be that relevant in South Africa

Editor's pick
Spotlight
18 June 2024
Young people

Caring, non-judgemental staff are the “magic ingredient” of youth-friendly HIV services

Editor's pick
Be In The Know
19 June 2024
Transgender people

Are trans men being forgotten in conversations about HIV prevention?

Editor's pick
Faculty of Public Health
19 June 2024
HIV prevention policy

HIV prevention drug uptake is slow. Can offering choices change that?

Editor's pick
Devex (requires free registration)
20 June 2024
Bad science & bogus treatments

Old report about overseas Filipino workers with HIV falsely linked to Dubai

Editor's pick
AFP Factcheck
20 June 2024
Mpox

South Africa Waits for Mpox Vaccines After Confirming Seven ‘Severe Cases’

Editor's pick
Health Policy Watch
20 June 2024
Injectable & long-acting PrEP

Gilead’s Twice-Yearly Lenacapavir Demonstrated 100% Efficacy and Superiority to Daily Truvada® for HIV Prevention

Editor's pick
Gilead Sciences press release
20 June 2024
Injectable & long-acting PrEP

Landmark Trial in South Africa and Uganda Finds Twice Yearly HIV Prevention Injection Safe and Highly Effective

Editor's pick
AVAC
20 June 2024
HIV testing programmes & uptake

In South Africa, traditional healers join the fight against HIV

Editor's pick
Associated Press
19 June 2024
Injectable & long-acting PrEP

“Long overdue long-acting products” A call to action to accelerate access to lenacapavir!

Editor's pick
AfroCAB
21 June 2024
Injectable & long-acting PrEP

Treatment Action Group Statement on Lenacapavir PrEP: Getting from Efficacy to Access Requires Generic Licensing and Cost Reductions

Editor's pick
Treatment Action Group
21 June 2024
Neurological & cognitive problems

What Criteria Should Describe HIV-Related Cognitive Impairment?

Editor's pick
TheBodyPro
21 June 2024
Pharmaceutical industry

Watch out, GSK. Gilead’s twice-yearly PrEP drug shows 100% efficacy for HIV prevention

Editor's pick
FiercePharma
21 June 2024
Injectable & long-acting PrEP

Access Planning in High-Incidence, Resource-Limited Countries for Lenacapavir for HIV Prevention

Editor's pick
Gilead Sciences press release
21 June 2024
Human rights

UNAIDS applauds Namibian Constitutional Court's decision to declare unconstitutional the law that had criminalised same-sex relationships

Editor's pick
UNAIDS
21 June 2024
Injectable & long-acting PrEP

ICWEA Statement on Gilead’s announcement of twice-yearly Lenacapavir (LEN) for HIV prevention.

Editor's pick
International Community of Women living with HIV Eastern Africa
21 June 2024
Injectable & long-acting PrEP

Unitaid calls for accelerated global access to long-acting HIV prevention drug lenacapavir after positive trial results

Editor's pick
Unitaid
21 June 2024
Confidentiality, consent & medical ethics

What does the London NHS hospitals data theft mean for patients?

Editor's pick
The Guardian
24 June 2024
Government, leadership & policy

UK: Labour manifesto drops key disability rights pledges

Editor's pick
Disability News Service
24 June 2024
Combatting stigma

Our Words Have Power—NIAID Embraces Respectful, Inclusive, and Person-First Language

Editor's pick
National Institute of Allergy and Infectious Diseases
24 June 2024
Vaginal rings & topical PrEP

Vaginal Ring for PrEP Found Effective and Safe During Pregnancy

Editor's pick
Infectious Disease Special Edition
24 June 2024
Improving HIV care

How Can Clinics improve HIV Care Engagement? New Research Sheds Some Light

Editor's pick
TheBodyPro
24 June 2024
PrEP policies & guidelines

Appeals court finds 'Obamacare' pillar unconstitutional in suit over HIV-prevention drug

Editor's pick
NBC News
24 June 2024
Injectable & long-acting PrEP

Statement From The Gilead’s Purpose 1 Global Community Accountability Board, The African Women’s Prevention Community Accountability Board, Our Partners And Community Partners

Editor's pick
African Women’s Prevention Community Accountability Board
24 June 2024